P. Chicaud et al., The beneficial effect of a beta-D-xyloside, iliparcil, in the prevention of postthrombolytic rethrombosis in the rat, HAEMOSTASIS, 28(6), 1998, pp. 313-320
The effect of Iliparcil, a new orally active beta-D-xyloside venous antithr
ombotic, was studied on the rethrombosis following thrombolytic therapy in
rats, using a modified Umetsu model. The drug was administered by oral rout
e prior to thrombolytic therapy, which consisted of administering a combina
tion of heparin and urokinase (H/U) at 37.5 and 70,000 IU/kg, respectively.
Time to reocclusion increased from 3.9 min with saline to 10.5 min followi
ng H/U injection. When Iliparcil (30 mg/kg, oral route) was administered 4
h before H/U injection, the time to reocclusion was increased by 250% compa
red with H/U alone (p < 0.001). Similarly, dermatan sulfate (DS), administe
red intravenously (3 mg/kg) 5 min before thrombus induction, also increased
the time to reocclusion (300% compared with H/U alone; p < 0.001). It was
also shown that times to reocclusion following Iliparcil or DS treatments w
ere still increased even when heparin dosage was decreased. These results s
uggest that an antithrombotic product derived from the beta-D-xyloside fami
ly could be advantageously used in combination with thrombolytic treatment
instead of heparin, which causes complications and side effects.